Argenx Se(NASDAQ) ARGX

argenx SE is a biotechnology company based in Amsterdam, dedicated to developing innovative therapies for autoimmune diseases. Established in 2008, the company operates in key global markets, including the United States, Europe, and Asia, with a focus on addressing a wide range of conditions through its advanced pipeline.

Products and Services

• Leading investigational therapy: efgartigimod for various autoimmune conditions
• Extensive pipeline including Empasiprubart and ARGX-119 for neurological disorders
• Proprietary products such as VYVGART and VYVGART HYTRULO

Growth Outlook

• Recent quarterly revenue reached $3.21 billion, showcasing strong market demand
• Net income for Q4 2025 was $1.05 billion, indicating robust profitability
• Strategic collaborations with major partners enhance research and market reach

Financial Highlights

• Trailing twelve months (TTM) revenue of $4.1 billion reflects significant growth
• Operating income margin of 26.5% demonstrates operational efficiency
• Cash and short-term investments total $4.44 billion, providing strong liquidity

The company’s commitment to innovation is evident in its diverse pipeline, which includes therapies targeting conditions such as generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The strategic partnerships with industry leaders further bolster its research capabilities and market presence. Recent financial performance highlights a strong revenue trajectory and profitability, positioning argenx SE as a compelling player in the biotechnology sector. With a solid cash position, the company is well-equipped to continue its growth and development initiatives.